Steven D. Wyrick - Concepedia

Author

Steven D. Wyrick

University of North Carolina at Chapel Hill

Also Known As

S D Wyrick, S Wyrick, S. D. WYRICK, S. D. Wyrick, S.D. Wyrick, Steven D Wyrick, Steven D. Wyrick, Steven Wyrick

Publications

Citations

H-Index

Concepts

All Affiliations

University of North Carolina at Chapel Hill

About

Steven D. Wyrick is an author at University of North Carolina at Chapel Hill specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	26	1K
2	Natural Sciences	11	11	448
3	Engineering	3	3	103
4	Health Sciences	2	2	56
5	Public Health	1	1	22

Steven D. Wyrick

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Christopher J. McBain, N W Kleckner, Steven D. Wyrick, Molecular Pharmacology	1989	166
Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Gregory R. Gibbons, Steven D. Wyrick, Stephen G. Chaney PubMed ChromatinMedicinal ChemistryRpmi 1640Bioorganic ChemistryBiochemistry	1989	88
In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Stephen G. Chaney, Steven D. Wyrick, G K Till PubMed Cancer Res.BiochemistryVitro BiotransformationsMedicineBioanalysis	1990	81
Quantitative Structure−Activity Relationship Modeling of Dopamine D<sub>1</sub>Antagonists Using Comparative Molecular Field Analysis, Genetic Algorithms−Partial Least-Squares, and K Nearest Neighbor Methods Brian T. Hoffman, Sung Jin Cho, Weifan Zheng, Journal of Medicinal Chemistry	1999	80
Synthesis and Molecular Modeling of 1-Phenyl-1,2,3,4-tetrahydroisoquinolines and Related 5,6,8,9-Tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 Dopamine Antagonists Deborah L. Minor, Steven D. Wyrick, Paul S. Charifson, Journal of Medicinal Chemistry Organic ChemistryPharmacotherapyChemistryHeterocycle ChemistryExperimental Pharmacology	1994	69
Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model Feng Luo, Steven D. Wyrick, Stephen G. Chaney Cancer Chemotherapy and Pharmacology MedicineComparative NeurotoxicityStem Cell ToxicologyBiotransformation ProductsToxicology	1999	65
Conformational Analysis of D<sub>1</sub> Dopamine Receptor Agonists: Pharmacophore Assessment and Receptor Mapping David Mottola, Sergei Laiter, Val J. Watts, Journal of Medicinal Chemistry Drug TargetLowest Energy ConformationPharmacophore AssessmentMolecular PharmacologyConformational Analysis	1996	64
[3H]SCH23390 has the characteristics of a dopamine receptor ligand in the rat central nervous system David W. Schulz, Steven D. Wyrick, Richard B. Mailman European Journal of Pharmacology Functional SelectivityMedicineNeuropeptide ReceptorNeuropharmacologyNeurology	1984	55
Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Stanley K. Mauldin, G F Gibbons, Steven D. Wyrick, PubMed L1210 Cell LineIntracellular Glutathione LevelsChemical BiologyPlatinum DrugsMedicinal Chemistry	1988	50
Hypolipidemic activity of in vitro inhibitors of hepatic and intestinal sn-glycerol-3-phosphate acyltransferase and phosphatidate phosphohydrolase Robert G. Lamb, Steven D. Wyrick, Claude A. Piantadosi Atherosclerosis Phosphatidate PhosphohydrolaseVitro InhibitorsBiochemistryLiver PhysiologyHypolipidemic Activity	1977	49

Page 1